Karmanos Cancer Institute serves as a sponsor of Wine & Dine in the D event to support multiple myeloma research
Monday, August 12, 2013
The Barbara Ann Karmanos Cancer Institute is once again a participating sponsor in the Third Annual Wine & Dine in the D, an evening of gourmet food, fine wine and the jazz vocals of Detroit’s Ursula Walker and the Buddy Budson Quintet hosted by the Multiple Myeloma Research Foundation (MMRF). The event takes place Thursday, September 19, 2013, at The Westin Book Cadillac in Detroit.
Karmanos is one of 16 members of the Multiple Myeloma Research Consortium (MMRC), an affiliate organization of MMRF, the world's leading funder of multiple myeloma research. The MMRF is committed to accelerating the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure.
The evening begins 5:30 p.m. with presentations by Jeffrey Zonder, M.D., associate professor of Medicine and Oncology at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine; Jeffrey Margolis, M.D., medical oncologist at Beaumont Hospital and professor at Oakland University-William Beaumont School of Medicine; and Michael Lill, M.D., head of stem cell research at Cedars-Sinai Hospital in Los Angeles and the staff of the Multiple Myeloma Research Foundation.
Dinner begins at 6:30 p.m. and includes specialties from some of metro Detroit’s top restaurants including 24 Grille, Andiamo, Assaggi Bistro, Baked Impressions, Beverly Hills Grill, Big Tommy’s Parthenon, Coach Insignia, Elie’s Mediterranean Grill/Bar, Eskimo Jacks Artisan Cookies & Ice Cream, Fleming’s Steakhouse & Wine Bar, Forest Grill, Giovanni’s Ristorante, Joe Muer Seafood, Maria’s Restaurant, Michael Symon’s Roast, Mitchell’s Fish Market, Ocean Prime, Pizzeria Biga, Rattlesnake Club, Ruth’s Chris Steakhouse, Stage Deli, Tre Monti Ristorante, Vicente’s Cuban Cuisine.
Sweet endings will be provided by Corden’s Candy Carousel and Rockey Mountain Chocolate Factory. Michigan wineries and microbreweries will be featured as well as boutique wines from around the world.
A patron and sponsor-only after-glow reception caps off the evening with desserts and cordials.
Tickets for Wine & Dine in the D are $175 each, or $275 for a Patron ticket, which allows the purchaser to attend the After-Glow Reception. In addition, special tickets are available for multiple myeloma patients. For more information or to purchase tickets, visit WineAndDineintheD.com or call Michele MacWilliams at (248) 625-0070.
The idea for Wine & Dine in the D came from its founder, Bloomfield Township resident Sid Moss, who has the disease and credits MMRF for providing him and other patients’ a quality of life that wasn’t attainable prior to the foundation’s research. Moss was diagnosed in 2009 with multiple myeloma. Currently in remission, he decided to organize a fundraising event to advance multiple myeloma research so more people can survive this disease.
About the Multiple Myeloma Research Consortium (MMRC)
The Multiple Myeloma Research Consortium (MMRC) is a 509(a)3 non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University. The MMRC was founded in 2004 by Kathy Giusti, a myeloma patient, and with the help of the scientific community. The MMRC is an affiliate organization of the Multiple Myeloma Research Foundation (MMRF), the world's leading funder of multiple myeloma research. The MMRC is widely recognized as an optimal research model to rapidly address critical challenges in drug development and to explore opportunities in today's most promising research areas – genomics, compound validation, and clinical trials. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit: www.themmrc.org.